160 related articles for article (PubMed ID: 38238599)
1. The quality of life of frequently vs. infrequently screened HPV vaccinated women.
Taavela K; Eriksson T; Huhtala H; Bly A; Harjula K; Heikkilä K; Hokkanen M; Nummela M; Kotaniemi-Talonen L; Lehtinen M; Louvanto K
Qual Life Res; 2024 Apr; 33(4):941-949. PubMed ID: 38238599
[TBL] [Abstract][Full Text] [Related]
2. The clinical effectiveness and cost-effectiveness of primary human papillomavirus cervical screening in England: extended follow-up of the ARTISTIC randomised trial cohort through three screening rounds.
C Kitchener H; Canfell K; Gilham C; Sargent A; Roberts C; Desai M; Peto J
Health Technol Assess; 2014 Apr; 18(23):1-196. PubMed ID: 24762804
[TBL] [Abstract][Full Text] [Related]
3. Cervical screening with primary HPV testing or cytology in a population of women in which those aged 33 years or younger had previously been offered HPV vaccination: Results of the Compass pilot randomised trial.
Canfell K; Caruana M; Gebski V; Darlington-Brown J; Heley S; Brotherton J; Gertig D; Jennett CJ; Farnsworth A; Tan J; Wrede CD; Castle PE; Saville M
PLoS Med; 2017 Sep; 14(9):e1002388. PubMed ID: 28926579
[TBL] [Abstract][Full Text] [Related]
4. National experience in the first two years of primary human papillomavirus (HPV) cervical screening in an HPV vaccinated population in Australia: observational study.
Smith MA; Sherrah M; Sultana F; Castle PE; Arbyn M; Gertig D; Caruana M; Wrede CD; Saville M; Canfell K
BMJ; 2022 Mar; 376():e068582. PubMed ID: 35354610
[TBL] [Abstract][Full Text] [Related]
5. Protocol for Compass: a randomised controlled trial of primary HPV testing versus cytology screening for cervical cancer in HPV-unvaccinated and vaccinated women aged 25-69 years living in Australia.
Canfell K; Saville M; Caruana M; Gebski V; Darlington-Brown J; Brotherton J; Heley S; Castle PE
BMJ Open; 2018 Jan; 8(1):e016700. PubMed ID: 29374658
[TBL] [Abstract][Full Text] [Related]
6. Performance of Cervical Screening a Decade Following HPV Vaccination: The Costa Rica Vaccine Trial.
Hu SY; Kreimer AR; Porras C; Guillén D; Alfaro M; Darragh TM; Stoler MH; Villegas LF; Ocampo R; Rodriguez AC; Schiffman M; Tsang SH; Lowy DR; Schiller JT; Schussler J; Quint W; Gail MH; Sampson JN; Hildesheim A; Herrero R;
J Natl Cancer Inst; 2022 Sep; 114(9):1253-1261. PubMed ID: 35640980
[TBL] [Abstract][Full Text] [Related]
7. Optimal Cervical Cancer Screening in Women Vaccinated Against Human Papillomavirus.
Kim JJ; Burger EA; Sy S; Campos NG
J Natl Cancer Inst; 2017 Feb; 109(2):. PubMed ID: 27754955
[TBL] [Abstract][Full Text] [Related]
8. Impact of cervical screening by human papillomavirus genotype: Population-based estimations.
Wang J; Elfström KM; Lagheden C; Eklund C; Sundström K; Sparén P; Dillner J
PLoS Med; 2023 Oct; 20(10):e1004304. PubMed ID: 37889928
[TBL] [Abstract][Full Text] [Related]
9. Effectiveness of HPV vaccination in women reaching screening age in Italy.
Carozzi FM; Ocello C; Burroni E; Faust H; Zappa M; Paci E; Iossa A; Bonanni P; Confortini M; Sani C
J Clin Virol; 2016 Nov; 84():74-81. PubMed ID: 27728850
[TBL] [Abstract][Full Text] [Related]
10. Adapting cervical cancer screening for women vaccinated against human papillomavirus infections: The value of stratifying guidelines.
Pedersen K; Burger EA; Nygård M; Kristiansen IS; Kim JJ
Eur J Cancer; 2018 Mar; 91():68-75. PubMed ID: 29335156
[TBL] [Abstract][Full Text] [Related]
11. Prophylactic vaccination against human papillomaviruses to prevent cervical cancer and its precursors.
Arbyn M; Xu L; Simoens C; Martin-Hirsch PP
Cochrane Database Syst Rev; 2018 May; 5(5):CD009069. PubMed ID: 29740819
[TBL] [Abstract][Full Text] [Related]
12. Comparison of human papillomavirus genotyping and cytology triage, COMPACT Study: Design, methods and baseline results in 14 642 women.
Aoyama-Kikawa S; Fujita H; Hanley SJB; Kasamo M; Kikuchi K; Torigoe T; Matsuno Y; Tamakoshi A; Sasaki T; Matsuura M; Kato Y; Dong P; Watari H; Saito T; Sengoku K; Sakuragi N
Cancer Sci; 2018 Jun; 109(6):2003-2012. PubMed ID: 29660849
[TBL] [Abstract][Full Text] [Related]
13. Randomised healthcare policy evaluation of organised primary human papillomavirus screening of women aged 56-60.
Lamin H; Eklund C; Elfström KM; Carlsten-Thor A; Hortlund M; Elfgren K; Törnberg S; Dillner J
BMJ Open; 2017 May; 7(5):e014788. PubMed ID: 28566363
[TBL] [Abstract][Full Text] [Related]
14. Predictors of Cervical Cancer Screening Among Infrequently Screened Women Completing Human Papillomavirus Self-Collection: My Body My Test-1.
Lea CS; Perez-Heydrich C; Des Marais AC; Richman AR; Barclay L; Brewer NT; Smith JS
J Womens Health (Larchmt); 2019 Aug; 28(8):1094-1104. PubMed ID: 30874477
[No Abstract] [Full Text] [Related]
15. How will transitioning from cytology to HPV testing change the balance between the benefits and harms of cervical cancer screening? Estimates of the impact on cervical cancer, treatment rates and adverse obstetric outcomes in Australia, a high vaccination coverage country.
Velentzis LS; Caruana M; Simms KT; Lew JB; Shi JF; Saville M; Smith MA; Lord SJ; Tan J; Bateson D; Quinn M; Canfell K
Int J Cancer; 2017 Dec; 141(12):2410-2422. PubMed ID: 28801947
[TBL] [Abstract][Full Text] [Related]
16. Cost-Utility of a Two-Dose Human Papillomavirus Vaccination Programme Added to Cervical Cancer Screening Compared with Cervical Cancer Screening Alone in Korea.
Lee H; Hur S; Jang H; Lee IH; Sohn WY; Van Kriekinge G; Kim BG
Asian Pac J Cancer Prev; 2019 Feb; 20(2):425-435. PubMed ID: 30803204
[TBL] [Abstract][Full Text] [Related]
17. What cervical screening is appropriate for women who have been vaccinated against high risk HPV? A simulation study.
Landy R; Windridge P; Gillman MS; Sasieni PD
Int J Cancer; 2018 Feb; 142(4):709-718. PubMed ID: 29023748
[TBL] [Abstract][Full Text] [Related]
18. Cost-effectiveness of primary human papillomavirus triage approaches among vaccinated women in Norway: A model-based analysis.
Portnoy A; Pedersen K; Sy S; Tropé A; Engesaeter B; Kim JJ; Burger EA
Int J Cancer; 2024 Mar; 154(6):1073-1081. PubMed ID: 38088449
[TBL] [Abstract][Full Text] [Related]
19. Age-specific effectiveness of primary human papillomavirus screening versus cytology in a cervical cancer screening program: a nationwide cross-sectional study.
Bao H; Ma L; Zhao Y; Song B; Di J; Wang L; Gao Y; Ren W; Wang S; Wu J; Wang HJ
Cancer Commun (Lond); 2022 Mar; 42(3):191-204. PubMed ID: 35142100
[TBL] [Abstract][Full Text] [Related]
20. Baseline findings and safety of infrequent vs. frequent screening of human papillomavirus vaccinated women.
Louvanto K; Eriksson T; Gray P; Apter D; Baussano I; Bly A; Harjula K; Heikkilä K; Hokkanen M; Huhtinen L; Ikonen M; Karttunen H; Nummela M; Söderlund-Strand A; Veivo U; Dillner J; Elfstöm M; Nieminen P; Lehtinen M
Int J Cancer; 2020 Jul; 147(2):440-447. PubMed ID: 31749143
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
